Segment Disclosure - Summary of Net Loss Related To Segment Expenses (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2025	Mar. 31, 2024
Segment Reporting Information [Line Items]
Collaboration revenue	$ 7,500	$ 0
Direct external research and development costs	61,200	44,250
Personnel-related expenses	22,640	14,854
Stock-based compensation expense	12,174	9,400
Other research and development costs	3,425	3,014
Other general and administrative costs	5,531	4,899
Interest income	(8,083)	(11,355)
Other segment items	392	245
Net loss	(65,047)	(47,931)
Azetukalner
Segment Reporting Information [Line Items]
Direct external research and development costs	31,501	23,213
Pre-clinical, discovery and other programs
Segment Reporting Information [Line Items]
Direct external research and development costs	$ 4,967	$ 3,661